首页 | 本学科首页   官方微博 | 高级检索  
     

抗CD20单克隆抗体诱导B淋巴瘤细胞株凋亡的实验研究
引用本文:张红雨,陈红涛,管忠震,黄岩,张星,林桐榆. 抗CD20单克隆抗体诱导B淋巴瘤细胞株凋亡的实验研究[J]. 中国实验血液学杂志, 2009, 17(4): 883-887
作者姓名:张红雨  陈红涛  管忠震  黄岩  张星  林桐榆
作者单位:1. 中山大学附属第五医院肿瘤化疗科,检验科,广东珠海,519000
2. 华南肿瘤学国家重点实验室,广东广州,510060;中山大学肿瘤防治中心内科,广东广州,510060
基金项目:广东省自然科学基金重点项目资助;编号05200178 
摘    要:本研究探讨抗CD20单克隆抗体体外诱导B淋巴细胞株凋亡情况及其可能的作用机制。体外培养Daudi、Ramos、Namalwa和Raji细胞,采用XTT法测定细胞增殖抑制率;用流式细胞术测定细胞凋亡;Western blot测定Daudi、Ramos、Raji和Namalwa细胞经Rituximab 20μg/ml作用24小时后Bcl-2的表达情况。结果表明:抗cD20单克隆抗体对Daudi、Raft和Namalwa淋巴瘤细胞有轻度的抗增殖作用,对Ramos细胞无抗增殖作用,抗增殖作用与单克隆抗体作用浓度无关。抗CD20单克隆抗体对4株细胞无明显诱导凋亡作用,抑制率在3%-10%之间波动。Na—malwa和Raji细胞株经抗CD20单克隆抗体作用24小时后,Bcl-2蛋白表达下调。结论:单药抗CD20单克隆抗体对Daudi、Namalwa和Raji细胞株有轻度抗细胞增殖作用,但与作用浓度和作用时间无明显相关。单药抗CD20单克隆抗体对Daudi、Namalwa、Raji和Ramos细胞株有微弱的诱导凋亡作用。Namalwa和Raji细胞株经抗CD20单克隆抗体作用24小时后Bcl-2表达下调,这可能是抗CD20单克隆抗体增敏细胞毒药物作用的机制之一。

关 键 词:抗CD20单克隆抗体  B淋巴细胞株  细胞凋亡

Preclinical Study of Apoptosis of B-NHL Cell Lines Induced by Anti-CD20 Monoclonal Antibody
ZHANG Hong-Yu,CHEN Hong-Tao,GUAN Zhong-Zhen,HUANG yan,ZHANG Xing,LIN Tong-Yu. Preclinical Study of Apoptosis of B-NHL Cell Lines Induced by Anti-CD20 Monoclonal Antibody[J]. Journal of experimental hematology, 2009, 17(4): 883-887
Authors:ZHANG Hong-Yu  CHEN Hong-Tao  GUAN Zhong-Zhen  HUANG yan  ZHANG Xing  LIN Tong-Yu
Affiliation:ZHANG Hong- Yu , CHEN Hong- Tao, GUAN Zhong-Zhen ,HUANG Yan ,ZHANG Xing ,LIN Tong- Yu (Departmant of Medical Oncology, Department of Laboratory Examination, The Fifth Hospital, SUN Yat-Sen University, Zhuhai 51900, Guangdong Province, China; 2 South China National Key Laboratory of Oncology, Guangzhou 510060, Guangdong Province, China ; 3 Department of Medical Oncology , Cancer Center, SUN Yat- San University, Guangzhou , 510060, Guangdong Province, China)
Abstract:The aim of this study was to investigate the effect of anti-CD20 monoclonal antibody (McAb) on induction of apoptosis in malignant B cell lines in vitro and to explore its possible mechanism. The human Burkitt' s lymphoma cell lines (Daudi, Namalwa, Raji and Ramos cells ) were cultured in vitro. The inhibitory rate of cell proliferation was detected by XTT assay, the apoptosis of cells was determined by flow cytometry. The expression of BCL-2 in human Burkitt's lymphoma cell lines (Daudi, Namalwa, Raji and Ramos cells) treated with rituximab(20 μg/ml) for 24 hours was analyzed by Western blot. The results showed that the anti-CD20 McAb had a slight antiproliferation effect on the Daudi, Namalwa, Raji cell lines and no effect on the Ramos cell line. There is no correlation between the effect and the concentration of anti-CD20 McAb. Anti-CD20 McAb as a single agent could weakly induce the apoptosis of four cell lines. The inhibitory rate of cell proliferation ranged from 3% to 10%. Expression of BCL-2 protein was down-regulated after treated by anti-CD20 McAb for 24 hours in Raji and Namalwa cell lines. It is concluded that the anti-CD20 McAb as a monomer can slightly inhibit the proliferation of Daudi, Namalwa and Raji cell lines, the inhibition does not dependent on the treating time and the concentrations of anti-CD20 McAb. Anti-CD20 McAb as a monomer can weakly induce the apoptosis of four cell lines. Expression of BCL-2 in Raji and Namalwa cell lines is down-regulated after the cells were treated by anti-CD20 McAb for 24 hours. Down-regulation of BCL-2 expression may be one of the mechanisms enhancing the cytotoxicity of cytotoxic drugs.
Keywords:rituximab  B cell lines  apoptosis
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号